RA306 is an orally active CAMK2 inhibitor that effectively disrupts the PEAK1/CAMK2 signaling pathway. It demonstrates anti-tumor activity by inhibiting proliferation, migration, and invasion of breast cancer cells. Additionally, RA306 shows potential in cardiac disease research, as it improves dilated cardiomyopathy in mice.
Target:
CaMK
* VAT and and shipping costs not included. Errors and price changes excepted
